These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7206225)

  • 21. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
    Alvares CL; Davies FE; Horton C; Patel G; Powles R; Sirohi B; Zuha R; Gatt A; Saso R; Treleaven JG; Dearden CE; Potter MN; Ethell ME; Morgan GJ
    Br J Haematol; 2005 Jun; 129(5):607-14. PubMed ID: 15916682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical study on chemotherapy for multiple myeloma. Part III: The disappearance of M-protein in multiple myeloma].
    Adachi T; Hasegawa M; Asano K; Sezaki T; Ishii H; Takahashi I; Kimura I
    Rinsho Ketsueki; 1983 Apr; 24(4):440-7. PubMed ID: 6887544
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical contribution the the therapy of multiple myeloma with phenylalanine mustard (melphalan)].
    Giardin A; Del Mela P; Morandi GA
    Riv Crit Clin Med; 1966 Aug; 66(3):244-54. PubMed ID: 6002407
    [No Abstract]   [Full Text] [Related]  

  • 25. [Melphalan in multiple myeloma].
    Ben-Bassat Y
    Harefuah; 1971 Feb; 80(3):141-3. PubMed ID: 5099255
    [No Abstract]   [Full Text] [Related]  

  • 26. Prognostic factors and survival in multiple myeloma. Analysis of 91 cases treated by melphalan and prednisone.
    Gobbi M; Cavo M; Savelli G; Baccarani M; Tura S
    Haematologica; 1980 Aug; 65(4):437-45. PubMed ID: 6774915
    [No Abstract]   [Full Text] [Related]  

  • 27. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
    Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC
    J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The treatment of multiple myeloma with melphalan].
    de Halleux F
    Presse Med (1893); 1967 Nov; 75(46):2307-10. PubMed ID: 6054150
    [No Abstract]   [Full Text] [Related]  

  • 30. Peptichemio in multiple myeloma. (Preliminary results).
    Cavo M; Gobbi M; Tura S
    Haematologica; 1981 Apr; 66(2):208-15. PubMed ID: 6791997
    [No Abstract]   [Full Text] [Related]  

  • 31. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment.
    Carlson K; Hjorth M; Knudsen LM;
    Br J Haematol; 2005 Mar; 128(5):631-5. PubMed ID: 15725084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [High-dose melphalan in patients with multiple myeloma].
    Moreau P; Le Bonniec M; Harousseau JL
    Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
    Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
    Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melphalan and its role in the management of patients with multiple myeloma.
    Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan.
    Vela-Ojeda J; García-Ruiz-Esparza MA; Padilla-González Y; Gómez-Almaguer D; Gutiérrez-Aguirre CH; Gómez-Rangel D; Morales-Toquero A; Ruiz-Delgado GJ; Delgado-Lamas JL; Ruiz-Argüelles GJ
    Ann Hematol; 2007 Apr; 86(4):277-82. PubMed ID: 17262193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.
    Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P
    Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapy of multiple myeloma].
    La Verde G; Pulsoni A; Petrucci MT; Mandelli F
    Recenti Prog Med; 1997 Apr; 88(4):186-93. PubMed ID: 9206817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Primary treatment results in myeloma disease using a cytostatic preparation].
    Iavorkovskiĭ LI; Soloveĭ DIa; Udris OIu; Riauzova LIu; Bliumental' RIa
    Probl Gematol Pereliv Krovi; 1981 Aug; 26(8):36-40. PubMed ID: 7301789
    [No Abstract]   [Full Text] [Related]  

  • 39. Palifermin dose should be adjusted to different therapy regimens.
    Verhagen MP; Wondergem MJ; Visser O
    Bone Marrow Transplant; 2009 Apr; 43(8):665. PubMed ID: 19029966
    [No Abstract]   [Full Text] [Related]  

  • 40. [Recent therapy for refractory myeloma].
    Togawa A
    Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.